Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

~30 mi. (Fresno, California, +744 more cities)

Kaiser Permanente-Fresno, +1 more facility

Breast Carcinoma

axillary lymph node dissection, +1 more drug

radiation therapy, +1 more type

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

~30 mi. (Fresno, California, +269 more cities)

Fresno Cancer Center

ER Positive, +1 more biomarker

Invasive Breast Carcinoma

radiation therapy, +1 more drug

radiation therapy

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

~30 mi. (Fresno, California, +233 more cities)

Kaiser Permanente-Fresno

Prostate Adenocarcinoma

degarelix, +4 more drugs

hormone therapy, +1 more type

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

~30 mi. (Fresno, California, +244 more cities)

Kaiser Permanente-Fresno, +1 more facility

Bladder Urothelial Carcinoma, +4 more conditions

atezolizumab, +4 more drugs

immunotherapy

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

~30 mi. (Fresno, California, +664 more cities)

Fresno Cancer Center, +1 more facility

PD-L1 High Expression (TPS >= 1%), +1 more biomarker

Non-Small Cell Lung Carcinoma

carboplatin, +2 more drugs

chemotherapy, +1 more type

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

~30 mi. (Fresno, California, +825 more cities)

Kaiser Permanente-Fresno, +1 more facility

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

~30 mi. (Fresno, California, +172 more cities)

VA of Central California Health Care System

Urothelial Carcinoma

cisplatin, +3 more drugs

chemotherapy, +1 more type

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

~30 mi. (Fresno, California, +128 more cities)

CCARE

del(11)(q10), +27 more biomarkers

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

parsaclisib, +1 more drug

targeted therapy

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

~30 mi. (Fresno, California, +260 more cities)

California Cancer Associate for Research & Excellence

ERBB2 Amplification, +1 more biomarker

Invasive Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

~30 mi. (Fresno, California, +160 more cities)

Fresno Cancer Center

Nasopharyngeal Carcinoma

cisplatin, +4 more drugs

chemotherapy, +1 more type

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

~30 mi. (Fresno, California, +280 more cities)

MorphoSys Research Site

ALK Fusion, +4 more biomarkers

ALK-Positive Large B-Cell Lymphoma, +7 more conditions

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

~30 mi. (Fresno, California, +606 more cities)

Kaiser Permanente-Fresno

CD274 Amplification

Angiosarcoma, +26 more conditions

ipilimumab, +1 more drug

immunotherapy